Outlook Therechtics的药量暴跌了80%, 因为它的湿AMD药物未能成功进行关键试验, Outlook Therapeutics’ stock plummeted 80% as its wet AMD drug failed key trial, though it saw vision improvements.

Outlook Therapeutics 的 ONS-5010 药物在针对罗氏 Lucentis 治疗湿性 AMD 的临床试验中未能达到主要终点后，其股价下跌了 80%。 Outlook Therapeutics’ stock dropped by 80% after its ONS-5010 drug failed to meet the primary endpoint in a clinical trial against Roche's Lucentis for treating wet AMD. 尽管遭受挫折,该公司注意到愿景和安全有所改善,预计2025年1月将取得全面成果。 Despite the setback, the company noted improvements in vision and safety, with full results expected in January 2025. 该公司计划在2025年第一季度重新提出美国批准申请,尽管它在欧洲已经获得批准。 The company plans to resubmit its application for U.S. approval in the first quarter of 2025, though it already has approval in Europe.